Clinical Cancer Research Bridging the Lab and the Clinic in Cancer Medicine Infection and Cancer: Biology, Therapeutics, and Prevention
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Disis, M. L.
Right arrow Articles by Cheever, M. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Disis, M. L.
Right arrow Articles by Cheever, M. A.
Clinical Cancer Research Vol. 5, 1289-1297, June 1999
© 1999 American Association for Cancer Research

Clinical Trials

Generation of Immunity to the HER-2/neu Oncogenic Protein in Patients with Breast and Ovarian Cancer Using a Peptide-based Vaccine1

Mary L. Disis2, Kenneth H. Grabstein, Paul R. Sleath and Martin A. Cheever

Division of Oncology, University of Washington, Seattle, Washington, 98195-6527 [M. L. D.], and Corixa Corporation, Seattle, Washington 98104 [K. H. G., P. R. S., M. A. C.]

HER-2/neu is a "self" tumor antigen that is overexpressed in 15–30% of human adenocarinomas. Vaccine strategies directed against HER-2/neu and other self tumor antigens require development of methods to overcome immune tolerance to self-proteins. In rats, rat neu peptide vaccines have been shown to be an effective way of circumventing tolerance to rat neu protein and generating rat neu-specific immunity. The present report validates that a similar peptide-based vaccine formulation is effective for inducing T-cell immunity to HER-2/neu protein in humans with breast and ovarian cancer. The vaccine formulation included groups of peptides derived from the HER-2/neu extracellular domain (ECD) or intracellular domain (ICD) mixed with granulocyte macrophage colony stimulating factor as an adjuvant. These peptides were 15–18 amino acids in length and designed to elicit a CD4 T helper-specific immune response. Patients underwent intradermal immunization once a month for a total of two to six immunizations. To date, all of the patients immunized with HER-2/neu peptides developed HER-2/neu peptide-specific T-cell responses. The majority of patients (six of eight) also developed HER-2/neu protein-specific responses. Responses to HER-2/neu protein occurred with epitope spreading. Immune T cells elicited by vaccination were shown to migrate outside the peripheral circulation by virtue of generating delayed type hypersensitivity responses distant from the vaccine site, which indicated the potential ability to traffic to the site of tumor. The use of peptide-based vaccines may be a simple, yet effective, vaccine strategy for immunizing humans to oncogenic self-proteins.




This article has been cited by other articles:


Home page
 JCOHome page
J. P. Holmes, L. C. Benavides, J. D. Gates, M. G. Carmichael, M. T. Hueman, E. A. Mittendorf, J. L. Murray, A. Amin, D. Craig, E. von Hofe, et al.
Results of the First Phase I Clinical Trial of the Novel Ii-Key Hybrid Preventive HER-2/neu Peptide (AE37) Vaccine
J. Clin. Oncol., July 10, 2008; 26(20): 3426 - 3433.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
K. R. Kalli, C. J. Krco, L. C. Hartmann, K. Goodman, M. J. Maurer, C. Yu, E. M. Johnson, C. L. Erskine, M. L. Disis, P. J. Wettstein, et al.
An HLA-DR-Degenerate Epitope Pool Detects Insulin-like Growth Factor Binding Protein 2-Specific Immunity in Patients with Cancer
Cancer Res., June 15, 2008; 68(12): 4893 - 4901.
[Abstract] [Full Text] [PDF]

Home page
 Exp. Biol. Med.Home page
J. Schlom, J. L. Gulley, and P. M. Arlen
Paradigm Shifts in Cancer Vaccine Therapy
Experimental Biology and Medicine, May 1, 2008; 233(5): 522 - 534.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
G. E. Peoples, J. P. Holmes, M. T. Hueman, E. A. Mittendorf, A. Amin, S. Khoo, Z. A. Dehqanzada, J. M. Gurney, M. M. Woll, G. B. Ryan, et al.
Combined Clinical Trial Results of a HER2/neu (E75) Vaccine for the Prevention of Recurrence in High-Risk Breast Cancer Patients: U.S. Military Cancer Institute Clinical Trials Group Study I-01 and I-02
Clin. Cancer Res., February 1, 2008; 14(3): 797 - 803.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
L. Vujanovic, M. Mandic, W. C. Olson, J. M. Kirkwood, and W. J. Storkus
A Mycoplasma Peptide Elicits Heteroclitic CD4+ T Cell Responses against Tumor Antigen MAGE-A6
Clin. Cancer Res., November 15, 2007; 13(22): 6796 - 6806.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
S. R. Kumar, T. P. Quinn, and S. L. Deutscher
Evaluation of an 111In-Radiolabeled Peptide as a Targeting and Imaging Agent for ErbB-2 Receptor Expressing Breast Carcinomas
Clin. Cancer Res., October 15, 2007; 13(20): 6070 - 6079.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
S. D. Allen, J. T. Garrett, S. V. Rawale, A. L. Jones, G. Phillips, G. Forni, J. C. Morris, R. G. Oshima, and P. T. P. Kaumaya
Peptide Vaccines of the HER-2/neu Dimerization Loop Are Effective in Inhibiting Mammary Tumor Growth In Vivo
J. Immunol., July 1, 2007; 179(1): 472 - 482.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
J. T. Garrett, S. Rawale, S. D. Allen, G. Phillips, G. Forni, J. C. Morris, and P. T. P. Kaumaya
Novel Engineered Trastuzumab Conformational Epitopes Demonstrate In Vitro and In Vivo Antitumor Properties against HER-2/neu
J. Immunol., June 1, 2007; 178(11): 7120 - 7131.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
S. Kitano, S. Kageyama, Y. Nagata, Y. Miyahara, A. Hiasa, H. Naota, S. Okumura, H. Imai, T. Shiraishi, M. Masuya, et al.
HER2-Specific T-Cell Immune Responses in Patients Vaccinated with Truncated HER2 Protein Complexed with Nanogels of Cholesteryl Pullulan
Clin. Cancer Res., December 15, 2006; 12(24): 7397 - 7405.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
K. L. Knutson, C. J. Krco, C. L. Erskine, K. Goodman, L. E. Kelemen, P. J. Wettstein, P. S. Low, L. C. Hartmann, and K. R. Kalli
T-Cell Immunity to the Folate Receptor Alpha Is Prevalent in Women With Breast or Ovarian Cancer
J. Clin. Oncol., September 10, 2006; 24(26): 4254 - 4261.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Surg. Oncol.Home page
E. A. Mittendorf, C. E. Storrer, C. D. Shriver, S. Ponniah, and G. E. Peoples
Investigating the Combination of Trastuzumab and HER2/neu Peptide Vaccines for the Treatment of Breast Cancer
Ann. Surg. Oncol., August 1, 2006; 13(8): 1085 - 1098.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
G. E. Peoples, J. M. Gurney, M. T. Hueman, M. M. Woll, G. B. Ryan, C. E. Storrer, C. Fisher, C. D. Shriver, C. G. Ioannides, and S. Ponniah
Clinical Trial Results of a HER2/neu (E75) Vaccine to Prevent Recurrence in High-Risk Breast Cancer Patients
J. Clin. Oncol., October 20, 2005; 23(30): 7536 - 7545.
[Abstract] [Full Text] [PDF]

Home page
 Protein Sci.Home page
S. Madurga, I. Belda, X. Llora, and E. Giralt
Design of enhanced agonists through the use of a new virtual screening method: Application to peptides that bind class I major histocompatibility complex (MHC) molecules
Protein Sci., August 1, 2005; 14(8): 2069 - 2079.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
K. L. Bondurant, M. D. Crew, A. D. Santin, T. J. O'Brien, and M. J. Cannon
Definition of an Immunogenic Region Within the Ovarian Tumor Antigen Stratum Corneum Chymotryptic Enzyme
Clin. Cancer Res., May 1, 2005; 11(9): 3446 - 3454.
[Abstract] [Full Text] [PDF]

Home page
 Endocr Relat CancerHome page
L A Emens, R T Reilly, and E M Jaffee
Breast cancer vaccines: maximizing cancer treatment by tapping into host immunity
Endocr. Relat. Cancer, March 1, 2005; 12(1): 1 - 17.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
N. K. Dakappagari, K. D. Lute, S. Rawale, J. T. Steele, S. D. Allen, G. Phillips, R. T. Reilly, and P. T. P. Kaumaya
Conformational HER-2/neu B-cell Epitope Peptide Vaccine Designed to Incorporate Two Native Disulfide Bonds Enhances Tumor Cell Binding and Antitumor Activities
J. Biol. Chem., January 7, 2005; 280(1): 54 - 63.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
A. B. Riemer, M. Klinger, S. Wagner, A. Bernhaus, L. Mazzucchelli, H. Pehamberger, O. Scheiner, C. C. Zielinski, and E. Jensen-Jarolim
Generation of Peptide Mimics of the Epitope Recognized by Trastuzumab on the Oncogenic Protein Her-2/neu
J. Immunol., July 1, 2004; 173(1): 394 - 401.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
C. De Giovanni, G. Nicoletti, L. Landuzzi, A. Astolfi, S. Croci, A. Comes, S. Ferrini, R. Meazza, M. Iezzi, E. Di Carlo, et al.
Immunoprevention of HER-2/neu Transgenic Mammary Carcinoma through an Interleukin 12-Engineered Allogeneic Cell Vaccine
Cancer Res., June 1, 2004; 64(11): 4001 - 4009.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
M. L. Disis, K. Schiffman, K. Guthrie, L. G. Salazar, K. L. Knutson, V. Goodell, C. dela Rosa, and M. A. Cheever
Effect of Dose on Immune Response in Patients Vaccinated With an HER-2/neu Intracellular Domain Protein--Based Vaccine
J. Clin. Oncol., May 15, 2004; 22(10): 1916 - 1925.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
K. Kono, E. Sato, H. Naganuma, A. Takahashi, K. Mimura, H. Nukui, and H. Fujii
Trastuzumab (Herceptin) Enhances Class I-Restricted Antigen Presentation Recognized by HER-2/neu-Specific T Cytotoxic Lymphocytes
Clin. Cancer Res., April 1, 2004; 10(7): 2538 - 2544.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
A. J. Reefer, R. M. Carneiro, N. J. Custis, T. A. E. Platts-Mills, S.-S. J. Sung, J. Hammer, and J. A. Woodfolk
A Role for IL-10-Mediated HLA-DR7-Restricted T Cell-Dependent Events in Development of the Modified Th2 Response to Cat Allergen
J. Immunol., March 1, 2004; 172(5): 2763 - 2772.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
M. Lomas, W. Liauw, D. Packham, K. Williams, A. Kelleher, J. Zaunders, and R. Ward
Phase I clinical trial of a human idiotypic p53 vaccine in patients with advanced malignancy
Ann. Onc., February 1, 2004; 15(2): 324 - 329.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
L. G. Salazar, J. Fikes, S. Southwood, G. Ishioka, K. L. Knutson, T. A. Gooley, K. Schiffman, and M. L. Disis
Immunization of Cancer Patients with HER-2/neu-Derived Peptides Demonstrating High-Affinity Binding to Multiple Class II Alleles
Clin. Cancer Res., November 15, 2003; 9(15): 5559 - 5565.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
M. E. Wolpoe, E. R. Lutz, A. M. Ercolini, S. Murata, S. E. Ivie, E. S. Garrett, L. A. Emens, E. M. Jaffee, and R. T. Reilly
HER-2/neu-Specific Monoclonal Antibodies Collaborate with HER-2/neu-Targeted Granulocyte Macrophage Colony-Stimulating Factor Secreting Whole Cell Vaccination to Augment CD8+ T Cell Effector Function and Tumor-Free Survival in Her-2/neu-Transgenic Mice
J. Immunol., August 15, 2003; 171(4): 2161 - 2169.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
V. Renard, L. Sonderbye, K. Ebbehoj, P. B. Rasmussen, K. Gregorius, T. Gottschalk, S. Mouritsen, A. Gautam, and D. R. Leach
HER-2 DNA and Protein Vaccines Containing Potent Th Cell Epitopes Induce Distinct Protective and Therapeutic Antitumor Responses in HER-2 Transgenic Mice
J. Immunol., August 1, 2003; 171(3): 1588 - 1595.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
N. K. Dakappagari, J. Pyles, R. Parihar, W. E. Carson, D. C. Young, and P. T. P. Kaumaya
A Chimeric Multi-Human Epidermal Growth Factor Receptor-2 B Cell Epitope Peptide Vaccine Mediates Superior Antitumor Responses
J. Immunol., April 15, 2003; 170(8): 4242 - 4253.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
S. A. Pilon, C. Kelly, and W.-Z. Wei
Broadening of Epitope Recognition During Immune Rejection of ErbB-2-Positive Tumor Prevents Growth of ErbB-2-Negative Tumor
J. Immunol., February 1, 2003; 170(3): 1202 - 1208.
[Abstract] [Full Text] [PDF]

Home page
 J. Leukoc. Biol.Home page
I. D. Davis, M. Jefford, P. Parente, and J. Cebon
Rational approaches to human cancer immunotherapy
J. Leukoc. Biol., January 1, 2003; 73(1): 3 - 29.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
J. L. Murray, M. E. Gillogly, D. Przepiorka, H. Brewer, N. K. Ibrahim, D. J. Booser, G. N. Hortobagyi, A. P. Kudelka, K. H. Grabstein, M. A. Cheever, et al.
Toxicity, Immunogenicity, and Induction of E75-specific Tumor-lytic CTLs by HER-2 Peptide E75 (369-377) Combined with Granulocyte Macrophage Colony-stimulating Factor in HLA-A2+ Patients with Metastatic Breast and Ovarian Cancer
Clin. Cancer Res., November 1, 2002; 8(11): 3407 - 3418.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
K. Kono, A. Takahashi, F. Ichihara, H. Sugai, H. Fujii, and Y. Matsumoto
Impaired Antibody-dependent Cellular Cytotoxicity Mediated by Herceptin in Patients with Gastric Cancer
Cancer Res., October 15, 2002; 62(20): 5813 - 5817.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
R. Konopitzky, U. Konig, R. G. Meyer, W. Sommergruber, T. Wolfel, and T. Schweighoffer
Identification of HLA-A*0201-Restricted T Cell Epitopes Derived from the Novel Overexpressed Tumor Antigen Calcium-Activated Chloride Channel 2
J. Immunol., July 1, 2002; 169(1): 540 - 547.
[Abstract] [Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
G. Parmiani, C. Castelli, P. Dalerba, R. Mortarini, L. Rivoltini, F. M. Marincola, and A. Anichini
Cancer Immunotherapy With Peptide-Based Vaccines: What Have We Achieved? Where Are We Going?
J Natl Cancer Inst, June 5, 2002; 94(11): 805 - 818.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
M. L. Disis, T. A. Gooley, K. Rinn, D. Davis, M. Piepkorn, M. A. Cheever, K. L. Knutson, and K. Schiffman
Generation of T-Cell Immunity to the HER-2/neu Protein After Active Immunization With HER-2/neu Peptide-Based Vaccines
J. Clin. Oncol., June 1, 2002; 20(11): 2624 - 2632.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
K. L. Knutson, K. Schiffman, M. A. Cheever, and M. L. Disis
Immunization of Cancer Patients with a HER-2/neu, HLA-A2 Peptide, p369-377, Results in Short-lived Peptide-specific Immunity
Clin. Cancer Res., May 1, 2002; 8(5): 1014 - 1018.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
M. L. Disis, K. Rinn, K. L. Knutson, D. Davis, D. Caron, C. dela Rosa, and K. Schiffman
Flt3 ligand as a vaccine adjuvant in association with HER-2/neu peptide-based vaccines in patients with HER-2/neu-overexpressing cancers
Blood, April 15, 2002; 99(8): 2845 - 2850.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
M. H. Manjili, R. Henderson, X.-Y. Wang, X. Chen, Y. Li, E. Repasky, L. Kazim, and J. R. Subjeck
Development of a Recombinant HSP110-HER-2/neu Vaccine Using the Chaperoning Properties of HSP110
Cancer Res., March 1, 2002; 62(6): 1737 - 1742.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
C. Meyer zum Buschenfelde, J. Metzger, C. Hermann, N. Nicklisch, C. Peschel, and H. Bernhard
The Generation of Both T Killer and Th Cell Clones Specific for the Tumor-Associated Antigen HER2 Using Retrovirally Transduced Dendritic Cells
J. Immunol., August 1, 2001; 167(3): 1712 - 1719.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
G. A. Ohnmacht, E. Wang, S. Mocellin, A. Abati, A. Filie, P. Fetsch, A. I. Riker, U. S. Kammula, S. A. Rosenberg, and F. M. Marincola
Short-Term Kinetics of Tumor Antigen Expression in Response to Vaccination
J. Immunol., August 1, 2001; 167(3): 1809 - 1820.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
D. G. McNeel, L. D. Nguyen, and M. L. Disis
Identification of T Helper Epitopes from Prostatic Acid Phosphatase
Cancer Res., July 1, 2001; 61(13): 5161 - 5167.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
T. M. Clay, A. C. Hobeika, P. J. Mosca, H. K. Lyerly, and M. A. Morse
Assays for Monitoring Cellular Immune Responses to Active Immunotherapy of Cancer
Clin. Cancer Res., May 1, 2001; 7(5): 1127 - 1135.
[Abstract] [Full Text]

Home page
 J. Immunol.Home page
Y. L. Yip, G. Smith, J. Koch, S. Dubel, and R. L. Ward
Identification of Epitope Regions Recognized by Tumor Inhibitory and Stimulatory Anti-ErbB-2 Monoclonal Antibodies: Implications for Vaccine Design
J. Immunol., April 15, 2001; 166(8): 5271 - 5278.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Pathol.Home page
I. Meinhold-Heerlein, F. Stenner-Liewen, H. Liewen, S. Kitada, M. Krajewska, S. Krajewski, J. M. Zapata, A. Monks, D. A. Scudiero, T. Bauknecht, et al.
Expression and Potential Role of Fas-Associated Phosphatase-1 in Ovarian Cancer
Am. J. Pathol., April 1, 2001; 158(4): 1335 - 1344.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
J.A. Sosman, P. Stiff, S.M. Moss, P. Sorokin, B. Martone, R. Bayer, K. van Besien, S. Devine, W. Stock, D. Peace, et al.
Pilot Trial of Interleukin-2 With Granulocyte Colony-Stimulating Factor for the Mobilization of Progenitor Cells in Advanced Breast Cancer Patients Undergoing High-Dose Chemotherapy: Expansion of Immune Effectors Within the Stem-Cell Graft and Post-Stem-Cell Infusion
J. Clin. Oncol., February 1, 2001; 19(3): 634 - 644.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
C. Meyer zum Buschenfelde, N. Nicklisch, S. Rose-John, C. Peschel, and H. Bernhard
Generation of Tumor-Reactive CTL Against the Tumor-Associated Antigen HER2 Using Retrovirally Transduced Dendritic Cells Derived from CD34+ Hemopoietic Progenitor Cells
J. Immunol., October 1, 2000; 165(7): 4133 - 4140.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
R. T. Reilly, M. B. C. Gottlieb, A. M. Ercolini, J.-P. H. Machiels, C. E. Kane, F. I. Okoye, W. J. Muller, K. H. Dixon, and E. M. Jaffee
HER-2/neu Is a Tumor Rejection Target in Tolerized HER-2/neu Transgenic Mice
Cancer Res., July 1, 2000; 60(13): 3569 - 3576.
[Abstract] [Full Text]

Home page
 Cancer Res.Home page
N. K. Dakappagari, D. B. Douglas, P. L. Triozzi, V. C. Stevens, and P. T. P. Kaumaya
Prevention of Mammary Tumors with a Chimeric HER-2 B-cell Epitope Peptide Vaccine
Cancer Res., July 1, 2000; 60(14): 3782 - 3789.
[Abstract] [Full Text]

Home page
 Clin. Cancer Res.Home page
G. E. Plautz, D. W. Miller, G. H. Barnett, G. H. J. Stevens, S. Maffett, J. Kim, P. A. Cohen, and S. Shu
T Cell Adoptive Immunotherapy of Newly Diagnosed Gliomas
Clin. Cancer Res., June 1, 2000; 6(6): 2209 - 2218.
[Abstract] [Full Text]

Home page
 JCOHome page
D. Lawson and J. M. Kirkwood
Granulocyte-Macrophage Colony-Stimulating Factor: Another Cytokine With Adjuvant Therapeutic Benefit in Melanoma?
J. Clin. Oncol., April 1, 2000; 18(8): 1603 - 1605.
[Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
M. L. Disis, K. Schiffman, T. A. Gooley, D. G. McNeel, K. Rinn, and K. L. Knutson
Delayed-Type Hypersensitivity Response Is a Predictor of Peripheral Blood T-Cell Immunity after HER-2/neu Peptide Immunization
Clin. Cancer Res., April 1, 2000; 6(4): 1347 - 1350.
[Abstract] [Full Text]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 1999 by the American Association for Cancer Research.